Sunesis Pharmaceuticals, Inc.
| Public | |
| Traded as | NASDAQ: SNSS |
| ISIN | 🆔 |
| Founded 📆 | |
| Founder 👔 | Jim Wells |
Area served 🗺️ | |
Key people | Daniel Swisher (2017; President & CEO)[1] |
| Members | |
Number of employees | |
| 🌐 Website | [Lua error in Module:WikidataIB at line 665: attempt to index field 'wikibase' (a nil value). ] |
| 📇 Address | |
| 📞 telephone | |
Sunesis Pharmaceuticals is a publicly held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecular therapeutics.[2] The company was founded in 1998 by Jim Wells,[3] who left Genentech to pursue this new opportunity.[4][5] Sunesis filed and completed an IPO in 2005.[6][7] It is listed on NASDAQ as SNSS.[6][8]
Pharmaceutical development[edit]
Sunesis uses a "tethering" drug-development platform, focused on a dynamic combinatorial chemistry method applied to the mutation of proteins, allowing for targeted delivery of drugs to patient tissues.[3]
In 2013, Sunesis was in the process of evaluating vosaroxin via clinical trials.[9] By May 2017, the company had submitted and withdrawn a European Marketing Authorization Application for this drug in the treatment of relapsed or recurrent acute myeloid leukemia.[1] The pivotal trial for vosaroxin failed to show demonstrable efficacy, which was its undoing.[1] Both the FDA and EMA had granted vosaroxin orphan drug status.[1]
Following this setback, the company's lead compound became SNS-062, also known as vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase aimed at helping leukemia patients with a C481S mutation that makes them less responsive to Ibrutinib, a generic drug with general efficiency in around 90% of patients.[1][2][10] Vecabrutinib was developed by Biogen Idec and licensed by Sunesis in 2014.[1]
In addition to vecabrutinib, the company's kinase inhibitor portfolio also includes SNS-229 and SNS-510, candidate drugs in pre-clinical development.[1]
Collaborations[edit]
Sunesis had two collaborations with Biogen Idec: the first, established in late 2002, concerned co-development of treatments for autoimmune and inflammatory diseases; the second, established in 2004, concerned codevelopment of kinase inhibitors for treatment of cancer.[11]
References[edit]
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Sunesis Withdraws European MAA for AML Drug Vosaroxin". Gen News Highlights. Genetic Engineering & Biotechnology News. 2 May 2017.
- ↑ 2.0 2.1 "Oppenheimer Starts Sunesis Pharmaceuticals Inc. (SNSS) at Outperform". Street Insider. 21 November 2017. Retrieved 2 July 2018.
- ↑ 3.0 3.1 Lowe, Derek (19 September 2008). "Sunesis: No Substitutions Allowed?". Science Translational Medicine. Retrieved 2 July 2018.
- ↑ Stockwell, Brent R. (2011). The Quest For The Cure: The Science and Stories Behind the Next Generation of Medicines. New York: Columbia University Press. p. 141. ISBN 978-0-231-52552-7. OCLC 714301737 – via Internet Archive. Search this book on
- ↑ "People In The News". GenomeWeb. New York. 11 December 2009. James Wells. Retrieved 12 July 2018.
- ↑ 6.0 6.1 "IPOs Planned". Wisconsin State Journal. Madison, Wisconsin. 18 September 2005. p. C4. Retrieved 7 July 2018 – via Newspapers.com (Publisher Extra).
- ↑ "Initial Public Offerings". Weekly Business Review. Austin American-Statesman. Austin, Texas. Associated Press. 17 September 2005. p. 3. Retrieved 1 July 2018 – via Newspapers.com (Publisher Extra).
- ↑ "Sunesis Pharmaceuticals Reports Fourth Quarter and Full Year 2005 Financial Results" (Press release). Sunesis Pharmaceuticals. 24 March 2006. Archived from the original on 29 September 2007.[self-published source]
- ↑ "Story Stocks". Business. The News Journal. Wilmington, Delaware. 14 March 2013. p. A11, Col 1. Retrieved 1 July 2018 – via Newspapers.com (Publisher Extra).
- ↑ "Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights". Seeking Alpha. GlobalNewsWire. 8 March 2018. Retrieved 1 July 2018.
- ↑ "Biogen Idec, Sunesis to collaborate on drugs". Commerce. The Ukiah Daily Journal. Ukiah, California. Dow Jones / Associated Press. 8 September 2004. p. 3, Col. 1. Retrieved 1 July 2018 – via Newspapers.com.
External links[edit]
 | This United States corporation or company article is a stub. You can help EverybodyWiki by expanding it. |
This article "Sunesis Pharmaceuticals" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Sunesis Pharmaceuticals. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
